Abstract | BACKGROUND: METHODS: Data were used from 1465 patients with COPD entered into a large 1 year double blind trial with daily measurements of peak expiratory flow (PEF) and symptom scores. RESULTS: PEF was significantly higher after 1 day in patients treated with salmeterol 50 microg twice daily or the salmeterol/ fluticasone propionate combination 50/500 microg twice daily than placebo. In patients treated with fluticasone propionate 500 microg twice daily alone, PEF differed from placebo after 2 days. The differences after 2 weeks compared with placebo were 16 l/min (95% confidence interval (CI) 11 to 21), 11 l/min (95% CI 6 to 16), and 27 l/min (95% CI 22 to 33) for salmeterol, fluticasone propionate, and the salmeterol/ fluticasone propionate combination, respectively. For all treatments the effect on PEF after 2 weeks was comparable to that seen at the end of the study. The difference between the salmeterol/ fluticasone propionate combination and placebo after 2 weeks as a percentage of baseline was similar for PEF and clinic forced expiratory volume in 1 second (FEV1). Differences in breathlessness scores were statistically significant after 1 day for the group treated with salmeterol alone and after 2 days for the combination group. The 2 week change in FEV1 was only partly indicative of a long term response in individual patients. CONCLUSIONS:
|
Authors | J Vestbo, R Pauwels, J A Anderson, P Jones, P Calverley, TRISTSAN study group |
Journal | Thorax
(Thorax)
Vol. 60
Issue 4
Pg. 301-4
(Apr 2005)
ISSN: 0040-6376 [Print] England |
PMID | 15790985
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Bronchodilator Agents
- Drug Combinations
- Salmeterol Xinafoate
- Fluticasone
- Albuterol
|
Topics |
- Administration, Inhalation
- Albuterol
(administration & dosage, analogs & derivatives)
- Analysis of Variance
- Androstadienes
(administration & dosage)
- Bronchodilator Agents
(administration & dosage)
- Double-Blind Method
- Drug Combinations
- Dyspnea
(drug therapy)
- Female
- Fluticasone
- Forced Expiratory Volume
(drug effects)
- Humans
- Male
- Middle Aged
- Peak Expiratory Flow Rate
(drug effects)
- Pulmonary Disease, Chronic Obstructive
(drug therapy, physiopathology)
- Salmeterol Xinafoate
- Treatment Outcome
- Vital Capacity
(drug effects)
|